Renal Cell Tumors: Molecular Findings Reshaping Clinico-pathological Practice

Tretiakova, Maria

doi:10.1016/j.arcmed.2020.08.003

Cited by 3 publications

(3 citation statements)

References 210 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PRCC is further subclassified histologically (and increasingly by molecular characteristics) into type 1 PRCC and type 2 PRCC [ 5 , 6 ]. Molecular alterations to MET are frequently found in type 1 including mutations and amplification with duplication of chromosome 7, the location of MET .…”

Section: Introductionmentioning

confidence: 99%

Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022

Maughan

2022

Curr Oncol Rep

View full text Add to dashboard Cite

Purpose of Review Historically, kidney cancer was diagnosed as either clear cell renal carcinoma (ccRCC) or non-clear cell renal carcinoma (nccRCC). With further research into the pathophysiology of nccRCC, multiple distinct subtypes have emerged creating distinct diagnosis, such as papillary renal cell carcinoma (PRCC), chromophobe renal cell carcinoma (crRCC), or unclassified carcinoma (cRCC). Many other kidney cancer subtypes are now included in the WHO classification system. Recent Findings The prognosis for each of the more frequently diagnosed types is discussed here along with treatment recommendations. The available clinical trial results and salient retrospective studies of each subtype are reviewed here to guide clinicians on the optimal treatment selection for patients with these rare histologic types or RCC. Summary Many nccRCC types are now recognized and each has unique molecular drivers which are different than ccRCC. The optimal treatment strategy is different for each subtype. The prognosis also differs based on the histology.

show abstract

Section: Introductionmentioning

confidence: 99%

Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022

Maughan

2022

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“…In adults, RCC is the most common type of kidney cancer, representing up to 90% of kidney cancer diagnoses, with at least 70% of cases being clear cell renal cell carcinoma (ccRCC), which represents most cases and produces the greatest number of deaths. It is identified because, in this tissue, cells appear under the microscope as clear or pale ( Tretiakova, 2020 ). Other subtypes of RCC, with different histology and development degree, are papillary.…”

Section: Introductionmentioning

confidence: 99%

“…Clear cells can range from grade 1 (slow tumor growth type) to grade 4 (fast tumor growth type) which is commonly associated with metastasis ( Karumanchi et al, 2002 ; DeVita et al, 2008 ). Likewise, there is a wide variety of specialized cells located throughout the nephron that can play a relevant role in the development of RCC, which is composed of several types of histological cells (reviewed in-depth by Tretiakova (2020) ). In fact, it has been demonstrated that both papillary RCC and ccRCC arise from the epithelium of the proximal tubule ( Cairns, 2011 ) ( Figure 1 ).…”

Section: Introductionmentioning

confidence: 99%

Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma

Osca-Verdegal

Beltrán-García²,

Górriz³

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Renal cell carcinoma is the most common type of kidney cancer, representing 90% of kidney cancer diagnoses, and the deadliest urological cancer. While the incidence and mortality rates by renal cell carcinoma are higher in men compared to women, in both sexes the clinical characteristics are the same, and usually unspecific, thereby hindering and delaying the diagnostic process and increasing the metastatic potential. Regarding treatment, surgical resection remains the main therapeutic strategy. However, even after radical nephrectomy, metastasis may still occur in some patients, with most metastatic renal cell carcinomas being resistant to chemotherapy and radiotherapy. Therefore, the identification of new biomarkers to help clinicians in the early detection, and treatment of renal cell carcinoma is essential. In this review, we describe circRNAs related to renal cell carcinoma processes reported to date and propose the use of some in therapeutic strategies for renal cell carcinoma treatment.

show abstract